To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
Public ClinicalTrials.gov record NCT02723591. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants maintained on twice daily, immediate-release tacrolimus versus those maintained on Astagraf XL in the first year post-transplant.
Study identification
- NCT ID
- NCT02723591
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 599 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 9, 2016 (Actual)
- Primary completion
- Jun 14, 2019 (Actual)
- Completion
- Jun 14, 2019 (Actual)
- Last update posted
- Dec 18, 2024
2016 – 2019
United States locations
- U.S. sites
- 30
- U.S. states
- 20
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US10006 | Birmingham | Alabama | 35294 | — |
| Site US10025 | Scottsdale | Arizona | 85259 | — |
| Site US10031 | Los Angeles | California | 90033 | — |
| Site US10005 | Sacramento | California | 95817 | — |
| Site US10016 | San Francisco | California | 94115 | — |
| Site US10024 | Aurora | Colorado | 80045 | — |
| Site US10003 | New Haven | Connecticut | 06510 | — |
| Site US10014 | Washington D.C. | District of Columbia | 20007 | — |
| Site US10030 | Jacksonville | Florida | 32224 | — |
| Site US10020 | Chicago | Illinois | 60605 | — |
| Site US10010 | Chicago | Illinois | 60611 | — |
| Site US10001 | Baltimore | Maryland | 21201 | — |
| Site US10007 | Boston | Massachusetts | 02114 | — |
| Site US10013 | Ann Arbor | Michigan | 48109 | — |
| Site US10032 | Detroit | Michigan | 48202 | — |
| Site US10029 | Minneapolis | Minnesota | 55455 | — |
| Site US10027 | Rochester | Minnesota | 55905 | — |
| Site US10019 | Livingston | New Jersey | 07039 | — |
| Site US10004 | Buffalo | New York | 14215 | — |
| Site US10037 | New York | New York | 10032 | — |
| Site US10022 | New York | New York | 10065 | — |
| Site US10028 | New York | New York | 10467 | — |
| Site US10021 | Syracuse | New York | 13210 | — |
| Site US10026 | Portland | Oregon | 97210 | — |
| Site US10002 | Charleston | South Carolina | 29425 | — |
| Site US10036 | Houston | Texas | 77030 | — |
| Site US10018 | Salt Lake City | Utah | 84112 | — |
| Site US10012 | Charlottesville | Virginia | 22903 | — |
| Site US10008 | Falls Church | Virginia | 22042 | — |
| Site US10023 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02723591, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02723591 live on ClinicalTrials.gov.